Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel
Sponsored by Johns Hopkins University
About this trial
Last updated 2 years ago
Study ID
IRB00284462
Status
Terminated
Type
Interventional
Phase
Phase 3
Placebo
No
Accepting
6+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 2 years ago
What is this trial about?
This study aims to evaluate the utility of long-acting liposomal bupivacaine (Exparel®) in
improving pain scores and reducing narcotic pain requirements in pediatric patients following
minor urologic procedures.
What are the participation requirements?
Inclusion Criteria
- Pediatric patients 6 years and older undergoing minor pediatric urologic surgery
- Patients who are otherwise eligible to receive routine care following minor urologic surgery
Exclusion Criteria
- Contraindication to receiving local anesthetics (i.e. pre-existing cardiac, renal, hepatic dysfunction)
- Pediatric patients younger than 6 years of age
- Pediatric patients with a history of pain syndromes or are unable to tolerate opiate medication
- Unwilling to participate in 48 hours and 10-14 day follow-up phone calls